HSPLS site	Login My List - 0 Help
	Search   My Account   Databases   HI Newspaper   eBooks/Audiobooks   Learning   PC Reservation   Reading Program

Basic Advanced Power History

Search:  Title BrowseAuthor BrowseSubject BrowseBest Seller BrowseMusic Title BrowseVideo/DVD Title BrowseJournal/Newspaper Title BrowseSerial Title BrowseSeries Browse (includes Bestseller List)General KeywordTitle KeywordAuthor KeywordSubject KeywordName KeywordSeries KeywordScore Title BrowseTalking Book Title BrowseAwards Note BrowseBib No.Barcode       Refine Search     > You're searching: HAWAII STATE PUBLIC LIBRARY SYSTEM

Item Information   Holdings     Summary     More Content       More by this author     Carreyrou, John, author.     Subjects     Theranos (Firm) -- History.     Hematologic equipment industry -- United States.     New business enterprises -- Corrupt practices -- United States -- Case studies.     Securities fraud -- United States -- Case studies.     Browse Catalog     by author:      Carreyrou, John, author.       by title:      Paedŭ pŭllŏdŭ : Tʻer...         MARC Display

Paedŭ pŭllŏdŭ : Tʻeranosŭ ŭi pimil kwa kŏjinmal / Jon Kʻaeriru chiŭm ; Pak A-rin omgim = Bad blood. by Carreyrou, John, author. Sŏul-si : Miraeen, 2019. Subjects Theranos (Firm) -- History.   Hematologic equipment industry -- United States.   New business enterprises -- Corrupt practices -- United States -- Case studies.   Securities fraud -- United States -- Case studies. ISBN:  9791164130696 (paperback) Description:  467 pages ; 22 cm Edition:  Chʻopʻan. Requests:  0 Summary:  In 2014, Theranos founder and CEO Elizabeth Holmes was widely seen as the female Steve Jobs: a brilliant Stanford dropout whose startup "unicorn" promised to revolutionize the medical industry with a machine that would make blood tests significantly faster and easier. Backed by investors such as Larry Ellison and Tim Draper, Theranos sold shares in a fundraising round that valued the company at $9 billion, putting Holmes's worth at an estimated $4.7 billion. There was just one problem: the technology didn't work. For years, Holmes had been misleading investors, FDA officials, and her own employees. When the author, working at The Wall Street Journal, got a tip from a former Theranos employee and started asking questions, both the author and the newspaper were threatened with lawsuits. Undaunted, the paper ran the first of dozens of Theranos articles in late 2015. By early 2017, the company's value was zero and Holmes faced potential legal action from the government and her investors. The biggest corporate fraud since Enron is a cautionary tale set amid the bold promises and gold-rush frenzy of Silicon Valley.   Copy/Holding information Location Collection Call No. Copy Status   McCully-Moiliili Public Library Korean Language K 338.76817 Ca [1369684] Checked In Add Copy to MyList

Horizon Information Portal 3.25_9884

© 2001-2013 SirsiDynix All rights reserved.